Landsteinerstrasse 5
Dreieich 63303
Germany
49 61 03 801 0
https://www.biotest.com
Settore/i:
Settore:
Impiegati a tempo pieno: 2.228
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Peter Janssen | Chairman of the Board of Management | 288k | N/D | 1968 |
Dr. Jorg Schuttrumpf | Chief Scientific Officer & Member of the Management Board | 581k | N/D | 1974 |
Dirk Schuck | Member of Supervisory Board | N/D | N/D | 1978 |
Ms. Ainhoa Mendizabal Zubiaga | Member of Management Board & CFO | N/D | N/D | 1973 |
Dr. Monika Buttkereit | Head of Investor Relations | N/D | N/D | N/D |
Dr. Christina Erb | Head of Corporate HR | N/D | N/D | N/D |
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
L'ISS Governance QualityScore di Biotest Aktiengesellschaft al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.